Discovering molecular targets in cancer with multiscale modeling

Drug Development Research

Volumn 72, Issue 1, 2011, Pages 45-52

  Wang, Zhihui ^a   Bordas, Veronika ^b   Deisboeck, Thomas S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD UNIVERSITY   (United States)

Author keywords

Computational modeling; Epidermal growth factor receptor; Multiscale; Non small cell lung cancer; Signaling pathway

Indexed keywords

ANALYTIC METHOD; CANCER MODEL; CANCER RESEARCH; CANCER THERAPY; COMPUTER MODEL; HUMAN; MOLECULAR DYNAMICS; MOLECULARLY TARGETED THERAPY; MULTISCALE MODELING; PHENOTYPE; REVIEW;

EID: 79951795485     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20401     Document Type: Review

References (49)

1. Alarcon T, Owen MR, Byrne HM, Maini PK. 2006. Multiscale modelling of tumour growth and therapy: the influence of vessel normalisation on chemotherapy. Comput Math Methods Med 7:85-119. (Pubitemid 44593983)
2. Allen LF, Sebolt-Leopold J, Meyer MB. 2003. CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin Oncol 30(5 Suppl 16):105-116.
3. Anderson AR, Weaver AM, Cummings PT, Quaranta V. 2006. Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell 127:905-915.
4. Araujo RP, Liotta LA, Petricoin EF. 2007. Proteins, drug targets and the mechanisms they control: the simple truth about complex networks. Nat Rev Drug Discov 6:871-880. (Pubitemid 350042395)
5. Bissell MJ, Radisky D. 2001. Putting tumours in context. Nat Rev Cancer 1:46-54. (Pubitemid 33741880)
6. Borisy AA, Elliott PJ, Hurst NW, Lee MS, Lehar J, Price ER, Serbedzija G, Zimmermann GR, Foley MA, Stockwell BR, et al. 2003. Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci USA 100:7977-7982. (Pubitemid 36760080)
7. Cho CR, Labow M, Reinhardt M, van Oostrum J, Peitsch MC. 2006. The application of systems biology to drug discovery. Curr Opin Chem Biol 10:294-302.
8. Chou TC. 2006. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58:621-681.
9. Couzin J. 2002. Cancer drugs. Smart weapons prove tough to design. Science 298:522-525.
10. Deisboeck TS, Zhang L, Martin S. 2007. Advancing cancer systems biology: introducing the Center for the Development of a Virtual Tumor, CViT. Cancer Inform 5:1-8.
11. Dittmar T, Husemann A, Schewe Y, Nofer JR, Niggemann B, Zanker KS, Brandt BH. 2002. Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c-erbB-2 receptor via EGFR. FASEB J 16:1823-1825.
12. Felip E, Santarpia M, Rosell R. 2007. Emerging drugs for non-small-cell lung cancer. Expert Opin Emerg Drugs 12:449-460. (Pubitemid 47527047)
13. Frey HC, Patil SR. 2002. Identification and review of sensitivity analysis methods. Risk Anal 22:553-578. (Pubitemid 34655123)
14. Gerlee P, Anderson AR. 2009. Evolution of cell motility in an individual-based model of tumour growth. J Theor Biol 259:67-83.
15. Green LJ, Marder P, Ray C, Cook CA, Jaken S, Musib LC, Herbst RS, Carducci M, Britten CD, Basche M, et al. 2006. Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor. Clin Cancer Res 12(11 Pt 1):3408-3415.
16. Guarino MJ, Schneider CJ, Hosford MA, Brahmer JR, Rudin CM, Finckenstein FG, Philip-Norton RE, Lu H, Weber MR, Ettinger DS. 2009. Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: a phase I study in patients with advanced solid malignancies. Oncologist 14:119-124.
17. Han SW, Hwang PG, Chung DH, Kim DW, Im SA, Kim YT, Kim TY, Heo DS, Bang YJ, Kim NK. 2005. Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer. Int J Cancer 113:109-115.
18. Helton JC, Johnson JD, Sallaberry CJ, Storlie CB. 2006. Survey of sampling-based methods for uncertainty and sensitivity analysis. Reliability Eng Syst Saf 91:1175-1209.
19. Hornberg JJ, Binder B, Bruggeman FJ, Schoeberl B, Heinrich R, Westerhoff HV. 2005. Control of MAPK signalling: from complexity to what really matters. Oncogene 24:5533-5542. (Pubitemid 43119348)
20. Hunter PJ, Borg TK. 2003. Integration from proteins to organs: the Physiome Project. Nat Rev Mol Cell Biol 4:237-243. (Pubitemid 36288045)
21. Keith CT, Borisy AA, Stockwell BR. 2005. Multicomponent therapeutics for networked systems. Nat Rev Drug Discov 4:71-78. (Pubitemid 40109591)
22. Kevrekidis IG, Samaey G. 2009. Equation-free multiscale computation: algorithms and applications. Annu Rev Phys Chem 60:321-344.
23. Lalonde RL, Kowalski KG, Hutmacher MM, Ewy W, Nichols DJ, Milligan PA, Corrigan BW, Lockwood PA, Marshall SA, Benincosa LJ, et al. 2007. Model-based drug development. Clin Pharmacol Ther 82:21-32. (Pubitemid 46950619)
24. Materi W, Wishart DS. 2007. Computational systems biology in drug discovery and development: methods and applications. Drug Discov Today 12:295-303. (Pubitemid 46467486)
25. McDermott U, Settleman J. 2009. Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology. J Clin Oncol 27:5650-5655.
26. Milton DT, Riely GJ, Azzoli CG, Gomez JE, Heelan RT, Kris MG, Krug LM, Pao W, Pizzo B, Rizvi NA, et al. 2007. Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer. Cancer 110:599-605. (Pubitemid 47106149)
27. Morabito A, Piccirillo MC, Falasconi F, De Feo G, Del Giudice A, Bryce J, Di Maio M, De Maio E, Normanno N, Perrone F. 2009. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist 14:378-390.
28. Nelander S, Wang W, Nilsson B, She QB, Pratilas C, Rosen N, Gennemark P, Sander C. 2008. Models from experiments: combinatorial drug perturbations of cancer cells. Mol Syst Biol 4:216.
29. Petricoin III EF, Bichsel VE, Calvert VS, Espina V, Winters M, Young L, Belluco C, Trock BJ, Lippman M, Fishman DA, et al. 2005. Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. J Clin Oncol 23:3614-3621.
30. Popel AS, Hunter PJ. 2009. Systems biology and physiome projects. Syst Biol Med 1:153-158.
31. Postovit LM, Seftor EA, Seftor RE, Hendrix MJ. 2006. Influence of the microenvironment on melanoma cell fate determination and phenotype. Cancer Res 66:7833-7836. (Pubitemid 44299141)
32. Rabitz H, Kramer M, Dacol D. 1983. Sensitivity analysis in chemical kinetics. Annu Rev Phys Chem 34:419-461.
33. Ramis-Conde I, Drasdo D, Anderson AR, Chaplain MA. 2008. Modeling the influence of the E-cadherin-beta-catenin pathway in cancer cell invasion: a multiscale approach. Biophys J 95:155-165.
34. Ramis-Conde I, Chaplain MA, Anderson AR, Drasdo D. 2009. Multi-scale modelling of cancer cell intravasation: the role of cadherins in metastasis. Phys Biol 6:16008.
35. Ren WQ, E WN. 2005. Heterogeneous multiscale method for the modeling of complex fluids and micro-fluidics. J Comput Phys 204:1-26.
36. Sanga S, Frieboes HB, Zheng X, Gatenby R, Bearer EL, Cristini V. 2007. Predictive oncology: a review of multidisciplinary, multiscale in silico modeling linking phenotype, morphology and growth. Neuroimage 37(Suppl 1):S120-S134.
37. Santos SD, Verveer PJ, Bastiaens PI. 2007. Growth factor-induced MAPK network topology shapes Erk response determining PC-12 cell fate. Nat Cell Biol 9:324-330. (Pubitemid 46344612)
38. Sioud M. 2007. Main approaches to target discovery and validation. Methods Mol Biol 360:1-12.
39. Smallbone K, Gatenby RA, Maini PK. 2008. Mathematical modelling of tumour acidity. J Theor Biol 255:106-112.
40. Tracqui P. 2009. Biophysical models of tumour growth. Rep Prog Phys 72:056701.
41. Turk B. 2006. Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov 5:785-799. (Pubitemid 44323703)
42. van Riel NA. 2006. Dynamic modelling and analysis of biochemical networks: mechanism-based models and model-based experiments. Brief Bioinform 7:364-374. (Pubitemid 44896739)
43. Walker DC, Southgate J. 2009. The virtual cell - a candidate coordinator for "middle-out" modelling of biological systems. Brief Bioinform 10:450-461.
44. Wang Z, Deisboeck TS. 2008. Computational modeling of brain tumors: discrete, continuum or hybrid? Sci Model Simul 15:381-393.
45. Wang Z, Zhang L, Sagotsky J, Deisboeck TS. 2007. Simulating non-small cell lung cancer with a multiscale agent-based model. Theor Biol Med Model 4:50.
46. Wang Z, Birch CM, Deisboeck TS. 2008. Cross-scale sensitivity analysis of a non-small cell lung cancer model: linking molecular signaling properties to cellular behavior. Biosystems 92:249-258.
47. Wang Z, Birch CM, Sagotsky J, Deisboeck TS. 2009. Cross-scale, cross-pathway evaluation using an agent-based non-small cell lung cancer model. Bioinformatics 25:2389-2396.
48. Wang Z, Bordas V, Sagotsky J, Deisboeck TS. 2010. Identifying therapeutic targets in a combined EGFR-TGFβR signaling cascade using a multiscale agent-based cancer model. Math Med Biol (in press).
49. Zhang L, Wang Z, Sagotsky JA, Deisboeck TS. 2009. Multiscale agent-based cancer modeling. J Math Biol 58:545-559.